NCT01526174View on ClinicalTrials.gov

Intratympanic Injection for Autoimmune Inner Ear Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

April 30, 2014

Conditions
Autoimmune Inner Ear Disease
Interventions
DRUG

Golimumab

Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections

Sponsors
All Listed Sponsors
collaborator

Janssen Services, LLC

INDUSTRY

lead

House Research Institute

OTHER